United Therapeutics Corporation (UTHR)

235,02 -1,98 (-0,84 %) À partir de 12:20PM EDT. Marché ouvert.

United Therapeutics Corporation

1000 Spring Street
Silver Spring, MD 20910
United States
301 608 9292
https://www.unither.com

Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 1 168

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D.	Founder, Chairman & CEO	5,32M	56,15M	1955
Mr. Michael I. Benkowitz	President & COO	2,83M	7,83M	1972
Mr. James C. Edgemond	CFO & Treasurer	2,01M	1,49M	1968
Mr. Paul A. Mahon J.D.	Executive VP, General Counsel & Corporate Secretary	2,31M	13,2M	1964
Mr. Dewey Steadman C.F.A.	Head of Investor Relations	S.O.	S.O.	S.O.
Ms. Holly Hobson	Associate Vice President of Human Resources	S.O.	S.O.	S.O.
Kevin T. Gray	Senior Vice President of Strategic Operations & Logistics	S.O.	S.O.	S.O.
Mr. Patrick Poisson	Executive VP of Technical Operations	S.O.	S.O.	1968
Dr. Leigh Peterson	Executive Vice President of Product Development & Xenotransplantation	S.O.	S.O.	S.O.
Mr. Gil Golden	Senior VP & Chief Medical Officer	S.O.	S.O.	S.O.

Les montants ont été établis en date du 31 décembre 2022 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en USD.

Description

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

Gouvernance d’entreprise

L’ISS Governance QualityScore de United Therapeutics Corporation en date du 1 avril 2024 est 2. Les scores principaux sont Audit : 1; Société : 5; Droits des actionnaires : 3; Compensation : 4.

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.